EAM Investors’s BioCryst Pharmaceuticals BCRX Stock Holding History

EAM Investors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-334,347	Closed	-$3M	–	264
2025 Q2	$3M	Buy	+334,347	New	+$3.11M	0.45%	108
2022 Q2	–	Sell	-162,969	Closed	-$2.65M	–	255
2022 Q1	$2.65M	Buy	+162,969	New	+$2.61M	0.49%	63
2021 Q4	–	Sell	-163,324	Closed	-$2.35M	–	292
2021 Q3	$2.35M	Sell	163,324 -86,532	-35%	-$1.36M	0.4%	80
2021 Q2	$3.95M	Buy	+249,856	New	+$3.39M	0.61%	22
2020 Q3	–	Sell	-563,961	Closed	-$2.69M	–	283
2020 Q2	$2.69M	Buy	+563,961	New	+$2.25M	0.59%	40
2019 Q2	–	Sell	-287,805	Closed	-$2.34M	–	256
2019 Q1	$2.34M	Sell	287,805 -16,472	-5%	-$141K	0.57%	47
2018 Q4	$2.46M	Buy	+304,277	New	+$2.37M	0.67%	30
2017 Q2	–	Sell	-109,625	Closed	-$921K	–	296
2017 Q1	$921K	Buy	+109,625	New	+$763K	0.15%	201
2015 Q4	–	Sell	-89,061	Closed	-$1.01M	–	312
2015 Q3	$1.01M	Sell	89,061 -27,908	-24%	-$372K	0.16%	261
2015 Q2	$1.75M	Buy	+116,969	New	+$1.33M	0.2%	200
2014 Q4	–	Sell	-85,721	Closed	-$838K	–	314
2014 Q3	$838K	Hold	85,721	–	–	0.17%	287
2014 Q2	$1.09M	Sell	85,721 -28,827	-25%	-$280K	0.21%	275
2014 Q1	$1.21M	Buy	+114,548	New	+$1.22M	0.22%	255
2013 Q4	–	Sell	-148,081	Closed	-$1.08M	–	311
2013 Q3	$1.08M	Buy	+148,081	New	+$751K	0.22%	238

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's BCRX Position: Q3 2025 in Review

EAM Investors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 334,347 shares — an estimated $3M sold.

EAM Investors first reported a position in BCRX in Q3 2013 and held it in 14 quarters. The position peaked at $3.95M in Q2 2021. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

EAM Investors reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
EAM Investors sold 334,347 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $3M.
EAM Investors first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 14 quarters.
EAM Investors's BioCryst Pharmaceuticals position peaked at $3.95M in Q2 2021.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on EAM Investors's 13F filing for Q3 2025, filed 14 Nov 2025.